Smith & Nephew gets FDA clearance to expand indications for devices Smith & Nephew announced that it has received FDA clearance to expand the indications within the hip for its innovative HEALICOIL PK Suture Anchor and OSTEORAPTOR Suture Anchor. Indications for the HEALICOIL PK Suture Anchor have been expanded to include abductor repair while those for the OSTEORAPTOR Suture Anchor now include labral reconstruction. Both products and new techniques will be showcased at this week's International Society for Hip Arthroscopy Annual meeting in Boston.
Smith & Nephew announces intended ratio change for ADRs Smith & Nephew announces an intended ratio change to its NYSE-listed American Depositary Receipt program. The ratio will change from the current one ADR per five ordinary shares to one ADR per two ordinary shares. The anticipated effective date for the ratio change is October 14. To implement the change, ADR holders on the record at the close of business one business day prior to the ratio change taking effect will receive 2.5 ADRs for every one ADR held.